87
Views
3
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Considerations on bringing warehoused HCV patients into active care following interferon-free, direct-acting antiviral drug approval

, &
Pages 471-475 | Received 17 Jan 2017, Accepted 07 Mar 2017, Published online: 15 Mar 2017

References

  • Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353–1363.
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
  • Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013;158:114–123.
  • Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (NY). 2011;7:154–162.
  • Aronsohn A, Jensen D. Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology. 2012;56:1591–1592.
  • Wilby KJ, Partovi N, Ford JAE, et al. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012;26(4):205–2010.
  • Alberti A, Colombo M, Craxi A, et al. The dilemma for patients with chronic hepatitis C: treat now or warehouse? Dig Liver Dis. 2014;46:27–29.
  • Gilead Sciences I. Sovaldi® (sofosbuvir) tablets, for oral use [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2015.
  • Poonsapaya JM, Einodshofer M, Kirkham HS, et al. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc. 2015;13:17.
  • Smith C, Brown S. ‘Warehousing’ in the HCV treatment landscape. Pharm Executive Global Dig. 2014 Nov;13–16.
  • Gilead Sciences I. Harvoni® (ledipasvir and sofosbuvir) tablets, for oral use [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2016.
  • US Department of Health and Human Services. Protection of human subjects 45 CFR §46.116 General requirements for informed consent. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.116
  • Vachon ML, Dietrich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis. 2011;31(4):399–409.
  • Denniston MM, Klevens RM, McQuillan GM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6):1652–1661.
  • Holmberg SD, Spradling PR, Moorman AC, et al. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–1861.
  • Hajarizadeh B, Grebely J, Martinello M, et al. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterop Hepatol. 2016;1:317–327.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.